Oncology diagnostics platform Elephas has raised $55 million in Series C funding, led by Venture Investors Health Fund and the State of Wisconsin Investment Board. Elephas focuses on predicting patient response to immunotherapy through metabolic imaging. The company analyzes tumor architecture via a patient biopsy and assesses potential therapies to determine treatment response. The funds will support Elephas in advancing its diagnostic platform and addressing the critical need for predicting immunotherapy response. The total funds raised by Elephas now amount to $116.5 million.
Elephas, an oncology-focused diagnostics platform, announced it secured $55 million in Series C funding, bringing its total raise to $116.5 million.
Venture Investors Health Fund and the State of Wisconsin Investment Board (SWIB) led the round.
Existing investors Northpond Ventures, Moore Strategic Ventures, WARF Ventures, Tao Invest, Sands Capital and ARCH Ventures also participated in the raise.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
WHAT IT DOES
Elephas is developing a diagnostics platform to predict a patient’s response to immunotherapy using metabolic imaging.
Immunotherapy is a therapeutic approach that helps the immune system fight cancer.
The Wisconsin-based company analyzes a tumor’s architecture via a patient biopsy and treats it with potential therapies to determine treatment response.
“The Elephas platform holds immense promise to address a critical unmet need in predicting response to immunotherapy,” Venture Investors Health Fund’s Paul Weiss said in a statement. “We are excited to work side by side with the company to pioneer a new diagnostic era for immunotherapy that will improve both access to therapy and outcomes for patients.”
MARKET SNAPSHOT
Immunotherapy is used to treat various types of cancers. Still, chemotherapy, radiation therapy and surgery are the more widely used forms of treatment, according to the National Cancer Institute.
Another company using emerging technologies to aid in the fight against cancer includes GE Healthcare, which announced a strategic partnership with Mayo Clinic in September, dubbed the Strategic Collaboration for Innovation in Medical Imaging and Theranostics. The collaboration focuses on advancing research and product development focusing on precision care, AI and theranostics.
Theranostics is an emerging technology and a form of precision medicine that fuses imaging technology with therapeutic agents to pinpoint and target cancer cells for destruction.
In November, GE Healthcare announced another collaboration, this time with Grand Rapids-based cancer treatment center BAMF Health, to advance the adoption of theranostics.
Source:Bio Space
